

Registered number: 03012351  
Charity number: 1044013

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**  
**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the company, its Trustees and advisers</b>	1
<b>Trustees' report</b>	2 - 13
<b>Independent auditor's report on the financial statements</b>	14 - 17
<b>Consolidated statement of financial activities</b>	18
<b>Consolidated balance sheet</b>	19
<b>Company balance sheet</b>	20
<b>Notes to the financial statements</b>	21 - 32

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

**(A company limited by guarantee)**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS**  
*FOR THE YEAR ENDED 31 MARCH 2021*

---

**Trustees**

Dr F MacKenzie  
Ms C Hodgson  
Dr R Hastings (resigned 18 November 2020)  
Dr P L Chiodini  
Mr A Dodson  
Dr B De la Salle  
Mr L Whitby, Chair  
Dr S Rughooputh (resigned 18 November 2020)  
Mrs D A Williams  
Mrs D Patel  
Dr R Marrington  
Mrs D Pritchard  
Ms F Khawaja (resigned 19 June 2020)  
Ms J Henderson (appointed 16 December 2020)  
Ms R Treacy (appointed 16 December 2020)

**Company registered number** 03012351

**Charity registered number** 1044013

**Registered office** 2 Rutland Park  
Sheffield  
S10 2PD

**Company secretary** Mrs J Gelder

**Independent auditor** BHP LLP  
Chartered Accountants  
2 Rutland Park  
Sheffield  
S10 2PD

**Bankers** Barclays Bank Plc  
Leicester  
LE87 2BB

---

## UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE

(A company limited by guarantee)

---

### TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2021

---

The Trustees present their annual report together with the audited financial statements of the company for the 1 April 2020 to 31 March 2021. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the group and the company qualify as small under section 383 of the Companies Act 2006, the Group strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

#### ***Objectives and activities***

##### **a. Objectives and activities**

United Kingdom National External Quality Assessment Service (UK NEQAS) aims to advance education and promote the preservation of good health by providing or securing the provision of external quality assessment services for clinical laboratories.

The UK NEQAS consortium has significant experience in provision of External Quality Assessment (EQA), having been established in 1969. Throughout its history UK NEQAS has led the way in the introduction of EQA programmes for numerous analytes, new types of EQA for qualitative, quantitative and interpretational aspects of clinical laboratory testing and is recognised as the world leader in provision of EQA.

The UK NEQAS organisation is governed by a Board of Trustees, elected from the membership and with one external member. In addition to directing the organisation, the Board of Trustees regularly review the organisation to ensure that UK NEQAS continues to meet its charitable aims, delivers a benefit to the public and meets the requirements of the Charity Commission. The Board of Trustees also implement new initiatives and direct the UK NEQAS organisation to promote harmonisation in working practices, development of EQA services, promotion of UK NEQAS and ensure adherence to the Code of Practice.

To direct and promote the aims of UK NEQAS, the membership appoints a President to be the Chair of the Board of Trustees. The President is elected by the membership in a closed ballot with candidates being members of or associated to a UK NEQAS centre. The current President, Mr Liam Whitby, took up the role at the UK NEQAS annual consortium in November 2018, he was re-elected for a second term of office ending in 2024. The President is supported in their role by 4 Vice-Presidents, the Board of Trustees and staff from UK NEQAS Central Office.

All members of the Board of Trustees receive no personal remuneration from the Charity for the time spent on UK NEQAS Board business, other than reimbursement of expenses and an agreed fixed backfill reimbursement to the employer of the President, to release time to undertake Presidential business as authorised by the Charity Commission.

---

## UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE

(A company limited by guarantee)

---

### TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

---

#### Objectives and activities (continued)

The EQA services provided by UK NEQAS are essential to supporting health services worldwide in their assessment and management of patients. Within the UK alone the NHS performs over one billion clinical laboratory tests a year, and over 95% of all clinical pathways rely on clinical laboratory results. As such, given the importance of clinical laboratory testing, the provision of a high standard EQA service is essential to healthcare. The EQA programmes operated by UK NEQAS not only support clinical laboratories in monitoring the quality of their results, but they also allow laboratories to benchmark their performance against users of other technologies and colleagues nationally and internationally. In addition, the programmes also provide laboratories with the tools necessary for continual audit of their services and for the education of staff.

The EQA services provided by UK NEQAS are open to all laboratories (public, private, research, veterinary) both within the UK and overseas. Instrument manufacturers, diagnostic reagent producers and pharmaceutical companies are also participants in UK NEQAS programmes, to enable them to monitor their products when they are used in the clinical laboratory environment or to assist in the development of new products. Allowing all laboratories to use UK NEQAS services means that patients worldwide can benefit from EQA delivered concurrently with educational aspects to inform users of best practices, resulting in improvements in healthcare delivery for all.

The membership of the UK NEQAS consortium consists of 18 expert centres located around the UK and hosted by a variety of institutions (NHS Trusts, Universities, Public Health England). All UK NEQAS member centres are accredited to ISO 17043 and operate according to the UK NEQAS Articles of Association and Code of Practice which require all EQA services to be provided on a not-for-profit basis with any operating surplus reinvested into EQA services.

Each UK NEQAS member has a dedicated Organiser responsible for the delivery of EQA services from that centre and accountable to the UK NEQAS Board of Trustees for ensuring their centre meets the UK NEQAS Articles and Code of Practice. Each Organiser is a registered scientist or clinician, with extensive experience in their field of EQA. In addition to an Organiser, each UK NEQAS centre is staffed by a dedicated team of scientists and administrative support staff working to ensure the delivery of the EQA services. Additional support and advice on development and operation of EQA programmes is provided by an independent steering committee of unpaid experts. These committees ensure that all UK NEQAS programmes remain clinically relevant in a developing laboratory environment and maintain the educational ethos that is at the heart of the organisation's values. Funding for the expert panels is met by the relevant UK NEQAS centre, with members of the steering committees receiving no personal remuneration from the Charity for their time other than reimbursement of expenses.

Additional external support and assistance is provided to UK NEQAS Organisers by the National Quality Assessment Advisory Panels (NQAAPs) and the Quality Assurance in Pathology Committee (QAPC). These stakeholder bodies, provided in partnership with other EQA providers and the Royal College of Pathologists (RCPATH), ensure that any performance issues occurring in UK laboratories are dealt with in a robust, consistent and supportive manner. Most of the operational funding of these panels in the UK is facilitated by the UK NEQAS Board of Trustees on behalf of the consortium and is paid for from member centres' precepts. However, it should be noted that to ensure operational independence members of the NQAAPs and the QAPC receive no personal remuneration from UK NEQAS. Whilst the NQAAP framework only applies to UK laboratories, UK NEQAS also works with regulatory oversight organisations in other countries to ensure that where such mechanisms exist, that they are used for the benefit of laboratories and patient safety to ensure any issues found as a result of EQA programmes are rapidly resolved for the good of all.

---

## UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE

(A company limited by guarantee)

---

### TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

---

#### Objectives and activities (continued)

In addition to updating content on the UK NEQAS website ([www.ukneqas.org.uk](http://www.ukneqas.org.uk)), the staff at Central Office continue to be responsible for the UK NEQAS Twitter feed (@UKNEQAS) and enhancing the UK NEQAS profile on LinkedIn by increasing the regularity of posts. UK NEQAS Central Office have been responsible for the delivery of UK NEQAS pan-disciplinary webinars and have facilitated the delivery of specialist online scientific meetings, ensuring that education remains the primary objective of the charity. Furthermore, Central Office continues to support the promotion and marketing of UK NEQAS services both nationally and internationally by producing harmonised marketing materials. Staff from Central Office are members of each UK NEQAS working group (I.T., Logistics, Marketing and Promotions, Point of Care Testing and Quality Management) and this ensures that the requirements of the charity are foremost in any developments, but also ensures consistency and promotes harmonisation across the organisation.

Communications between the UK NEQAS Board and the Pathology Quality Assessment (PQA) board (the trading company of UK NEQAS) is facilitated by regular meetings of both Boards and by having 3 members of the UK NEQAS Board of Trustees also being members of the PQA board.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

#### b. Activities and performance

- Rapidly developed and introduced a suite of Covid-19 EQA programmes and educational modules in response to the Covid-19 pandemic
- Continued delivery of EQA programmes during the Covid-19 pandemic and lockdown
- Continued collaborative working with stakeholders including RCPATH, MHRA, United Kingdom Accreditation Service (UKAS), Association of Clinical Biochemistry (ACB) and Institute of Biomedical Science (IBMS) to deliver improved quality outcomes for patients via improvements to the NQAAP and QAPC frameworks
- Continued delivery of multiple new genetic testing EQA programmes to meet the requirements of the NHSE and the National Genetics Testing Catalogue
- Ensured continuity of Central Office functions by the introduction of remote working
- Successfully implemented a marketing database
- Developed a series of pan-disciplinary webinars
- Supported UK NEQAS centres to deliver webinars
- Ensured continual updates to the UK NEQAS website
- Updated the financial software package used at Central Office
- Introduced virtual meetings for all working group and board meetings

#### c. Events

- During October and November, delivered series of eight pan-disciplinary webinars on the theme of Reducing Pre-Analytical Errors in Laboratory Medicine
  - Delivered to a combined audience of approximately 2,100 delegates
- Presented a webinar on Covid-19 EQA delivery for IBMS Biomedical Scientist Live
- Restructured AGM to be a virtual event due to Covid-19 national restrictions

---

## UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE

(A company limited by guarantee)

---

### TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

---

#### Objectives and activities (continued)

##### d. Working Groups

The I.T., Logistics, Marketing and Promotions, Point of Care Testing and Quality Management working groups all had online meetings in the period 2020-2021. This allowed them to continue to share experience across the organisation and co-ordinate new work packages to improve service delivery and promote harmonization.

We have continued to support and assist our scheme Organisers in their local arrangements with their hosts during the year.

The past year has seen the retirement of the following Organiser and Manager from their roles within several UK NEQAS centres:

- Professor Bill Egner (Immunology, Immunochemistry & Allergy)

UK NEQAS and Board has supported this centre in their transition to new leadership by ensuring that any appointments of organisers followed the UK NEQAS Articles of Association and the Code of Practice, confirming that the appointees were sufficiently qualified to meet the high professional standards needed to be a UK NEQAS organiser.

Through our members, we have continued the expansion of our EQA repertoire for the benefit of the participants. The Board has approved 22 new pilot programmes in 2020-2021

The Board of Trustees held 7 meetings during the year (meetings 179 - 185) online.

International collaborative working has continued through both members and Board of Trustees with collaborations in place with international bodies such as:

- EuroBloodNet
- European Centre for Disease Prevention and Control (ECDC)
- European Committee for External Quality Assurance (EQALM)
- European Society for Human Genetics (ESHG)
- European Society of Human Reproduction and Embryology
- International Council for Standardisation in Haematology (ICSH)
- International Cytometry Society (ICSH)
- International Laboratory Accreditation Cooperation (ILAC)
- International Society for Laboratory Haematology
- International Society of Blood Transfusion (ISBT)
- International System for Human Cytogenomic Nomenclature (ISCN)
- Joint Committee for Traceability in Laboratory Medicine (JCTLM)
- National Institutes for Health (NIH)
- Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP)
- Serious Hazards of Transfusion (SHOT)
- World Federation of Haemophilia (WFH)
- World Health Organisation (WHO)

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE****(A company limited by guarantee)**

---

**TRUSTEES' REPORT (CONTINUED)**  
*FOR THE YEAR ENDED 31 MARCH 2021*

---

**Objectives and activities (continued)**

The UK NEQAS Consortium hosted a number of virtual scientific meetings during 2020-2021, reaching over 15,000 delegates worldwide:

Centre	Event Title	Date	Platform
UK NEQAS Pan-Disciplinary	Harmonisation of the Pre-Analytical Phase and the Role of EFLM *	8 <sup>th</sup> October 2020	Zoom
	ISO15189 and the Pre-Analytical Phase *	15 <sup>th</sup> October 2020	
	Serum Indices *	22 <sup>nd</sup> October 2020	
	Sample Stability *	29 <sup>th</sup> October 2020	
	Reducing Sample Rejections Due to Pre-Analytical Errors: GOSH Experience *	5 <sup>th</sup> November 2020	
	Managing Transgender Reference Ranges *		
	Pre-Analytics in Coagulation *	12 <sup>th</sup> November 2020	
	PREPQ *	19 <sup>th</sup> November 2020	
	What Data do we Need and How do we Get it? *	26 <sup>th</sup> November 2020	
UK NEQAS Immunology, Immunochemistry & Allergy	Cryoproteins Masterclass *	23 <sup>rd</sup> November 2020	Zoom
UK NEQAS Blood Transfusion Laboratory Practice	BTLP Scheme Update *	24 <sup>th</sup> November 2020	Zoom
UK NEQAS Immunocytochemistry & In-Situ Hybridisation	UK NEQAS Molecular Forum	9 <sup>th</sup> March 2021	Zoom
UK NEQAS Haematology	UK NEQAS Morphology with the Experts *	9 <sup>th</sup> March 2021	Zoom

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

**(A company limited by guarantee)**

---

TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 MARCH 2021

---

**Objectives and activities (continued)**

Centre	Event Title	Date	Platform
	Troubleshooting Haematology EQA *	16 <sup>th</sup> March 2021	
	Haemoglobinopathy EQA Cases *	23 <sup>rd</sup> March 2021	
UK NEQAS Reproductive Science	Annual Participants' Meeting	11 <sup>th</sup> March 2021	Microsoft Teams
GenQA	Focus on EQAs for Molecular Genetics	19 <sup>th</sup> June 2020	Google Meet
	Lessons learned from 2019 worldwide EQA for Molecular Testing of BRCA Genes in Ovarian Cancer (vGermline & vSomatic)	1 <sup>st</sup> July 2020	
	Focus on Clinical Genetics – ensuring the quality of the entire genetics service	23 <sup>rd</sup> July 2020	
	Focus on Haematological neoplasms disorders	24 <sup>th</sup> August 2020	
	Focus on Preimplantation Genetic Testing – overview of 10 years of provision of PGT EQAs	30 <sup>th</sup> September 2020	
	Molecular Pathology – NTRK	29 <sup>th</sup> October 2020	
	BRCA Variant Classification assessment Run 5 masterclass webinar	25 <sup>th</sup> November 2020	Zoom
	Focus on molecular newborn screenings EQAs	30 <sup>th</sup> November 2020	Google Meet
	BRCA Variant Classification assessment Run 5 results	10 December 2020	Zoom
	Focus on Individual Competency assessment – BRCA Variant Classification assessment Run 4	17 December 2020	Google Meet
	Focus on EQA for ISCN – review of updated nomenclature in ISCN 2020	27 January 2021	
	Focus on Quality – Using EQA to improve your diagnostic service	24 February 2021	

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

**(A company limited by guarantee)**

---

TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 MARCH 2021

---

**Objectives and activities (continued)**

Centre	Event Title	Date	Platform
	Focus on Molecular Pathology: RET testing	22 March 2021	
Cellular Pathology Technique	Introduction to Specialist Demonstration Techniques (Taster Webinar)	17/06/2020 14/07/2020	Zoom
	Specialist Workshop A & B (Taster Webinar)	19 & 23/06/2020 16 & 21/07/2020	
	Introduction to Immunocytochemistry (Taster Webinar)	25/06/2020 23/07/2020	
	Introduction to Cellular Components Part 1, 2 & 3 (Taster Webinar)	02, 07 & 09/07/2020 15, 22 & 24/07/2020	
	Controlling Your Controls (Taster Webinar)	05/08/2020 10/09/2020	
	Troubleshooting in Demonstration Techniques: Reticulin (Taster Webinar)	06/08/2020 08/09/2020	
	Diagnostic Cytology Beginners/Refresher (Taster Webinar)	10/08/2020	
	Specimen Dissection (Taster Webinar)	18/08/2020	
	Troubleshooting in Demonstration Techniques: PAS/DPAS (Taster Webinar)	20/08/2020	
	BMT Introductory (Taster Webinar)	26/08/2020	
	Mohs Introductory (Taster Webinar)	02/09/2020	
	Renal Introductory (Taster Webinar)	03/09/2020	
	Transmission Electron Microscopy (Taster Webinar)	09/09/2020	
	Frozen (Muscle) (Taster Webinar)	22/09/2020	

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE****(A company limited by guarantee)**

---

TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 MARCH 2021

---

**Objectives and activities (continued)**

Centre	Event Title	Date	Platform
	Diagnostic Cytology Intermediate/Troubleshooting (Taster Webinar)	24/09/2020	
	Amyloid (Taster Webinar)	28/09/2020	
	Introduction to Cellular Components, Tissue Morphology and Tissue Recognition Part 1 & 2	07 to 08/10/2020	
	Mohs Introductory	14/10/2020	
	Amyloid	27 to 29/10/2020	
	Renal Introductory	28/10/2020	
	Virtual Participant Meeting	03/11/2020	
	Introduction to Specialist Demonstration Techniques	10 to 11/11/2020	
	Diagnostic Cytology Beginners/Refresher	11/11/2020	
	Diagnostic Cytology Intermediate/Troubleshooting	12/11/2020	
	BMT Introductory	16/11/2020	
	Specialist Workshop A & B	17 to 18/11/2020 24 to 25/11/2020	
	Transmission Electron Microscopy	25/11/2020	
	Introduction to Cellular Components, Tissue Morphology and Tissue Recognition Part 1 & 2	27/11/2020 09/12/2020	
	Introduction to Immunocytochemistry	02 to 07/12/2020	
	Fresh Muscle Biopsies	10/12/2020	

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

(A company limited by guarantee)

---

**TRUSTEES' REPORT (CONTINUED)**  
*FOR THE YEAR ENDED 31 MARCH 2021*

---

**Objectives and activities (continued)**

Centre	Event Title	Date	Platform
	ICC Technical Issues and Quality Assurance	11 to 13/01/2021	
	ICC Applications In Laboratory Practice	18 to 20/01/2021	

\* supported by UK NEQAS Central Office

***Achievements and performance*****a. Investment policy**

Under the Memorandum and Articles of Association, the charity has the power to invest in any way the trustees wish. The trustees, having regard to the liquidity requirement of operating the charity and to the reserves policy, have operated a policy of keeping available funds in an interest bearing deposit accounts with UK Banks and seeking to achieve the maximum possible rate of interest.

***Financial review*****a. Going concern**

After making appropriate enquiries, the trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

**b. Financial performance**

The charity had a surplus of £33,303 (2020: £72,286 deficit) in the year ended 31 March 2021. At 31 March 2021, it has reserves to carry forward of £181,946.

**c. Reserves policy**

The trustees have previously agreed that the minimum level of unrestricted reserves should be the equivalent of 60% of one year's operating costs.

Given an average yearly operating cost of approximately £260,000, the 60% reserve would equate to £156,000. Thus, at the beginning of financial year 2021-22 we will be operating with an actual reserve of 116.6% of the ideal figure.

Consideration was given to the reserve figure at 31 March 2021 and the fact that it is not in line with the stated target of 60% of expenditure. It was concluded that the COVID pandemic and the unforeseeable corresponding effects it had on the Charity's activities have caused a temporary decrease in expenditure. This was particularly associated with the suspension of all face-to-face meetings including the annual consortium, steering and advisory board meetings. A reinstatement of some meeting and their associated costs in the forthcoming year will have a redressing effect on reserves going forward.

---

## UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE

(A company limited by guarantee)

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

---

#### ***Structure, governance and management***

##### **a. Constitution**

The company and the group is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association.

The company and the group is constituted under a Memorandum of Association and is a registered charity number 1044013

##### **b. Methods of appointment or election of Trustees**

The management of the company and the group is the responsibility of the Trustees who are elected and co-opted under the terms of the Articles of Association.

The directors of the company, who are also trustees for the purposes of charity law and under the company's Articles, are known as members of the Executive Committee. Under the requirements of the Memorandum and Articles of Association, the members of the Board of Trustees holding office under either Article 25.1.2 or 25.1.3 shall retire from office at the 4th (fourth) annual general meeting following the commencement of his or her term of office. When considering co-opting trustees, the Executive Committee has regard to the requirement for any specialist skills needed and wider experience of the charity sector.

##### **c. Policies adopted for the induction and training of Trustees**

Most trustees are already familiar with the work of the charity and have knowledge of work that the charity undertakes and charity governance. New trustees are given an information pack containing information from the various Charity Commission Publications along with the Memorandum and Articles of Association.

##### **d. Organisational structure and decision making**

The Executive Committee are responsible for setting the strategic objectives and establishing policy. The Committee meets up to six times a year and delegates the day-to-day running of the organisation to the Executive Manager and staff at the UKNEQAS office in Sheffield.

##### **e. Risk management**

The directors have assessed the risks to which the charity is exposed, in particular those related to the operations and finances of the company, and are of the opinion that systems are in place to minimise the charity's exposure to these risks. Internal control risks are minimised by the implementation of procedures for authorisation of all transactions and projects. Procedures are in place to ensure compliance with health and safety of all staff, clients and visitors.

---

## UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE

(A company limited by guarantee)

---

### TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

---

#### Structure, governance and management (continued)

##### Plans for future periods

- Continued collaborative working with stakeholders to deliver improved quality outcomes for patients via improvements to the NQAAP and QAPC frameworks
- Pan-disciplinary UK NEQAS events
- Phased return to face-to-face presence at scientific meetings
- Harmonisation of packaging appearance and shipping documentation
- Create Emergency Planning for Service Continuity (central and local) relating to staff, accommodation and other circumstances
- Create central online repository of knowledge/webinars

##### Statement of Trustees' responsibilities

The Trustees (who are also the directors of the company for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the company and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

##### Disclosure of information to auditor

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable group's auditor is unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable group's auditor is aware of that information.

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

---

**TRUSTEES' REPORT (CONTINUED)**  
*FOR THE YEAR ENDED 31 MARCH 2021*

---

Approved by order of the members of the board of Trustees and signed on their behalf by:

.....  
**Mr L Whitby**

Date:

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

**(A company limited by guarantee)**

---

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

---

**Opinion**

We have audited the financial statements of United Kingdom National External Quality Assessment Service (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 March 2021 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2021 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities Act 2011.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

**(A company limited by guarantee)**

---

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE (CONTINUED)**

---

**Other information**

The other information comprises the information included in the Annual report other than the financial statements and our Auditor's report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Opinion on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the directors' report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a Strategic report.

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

**(A company limited by guarantee)**

---

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE (CONTINUED)**

---

**Responsibilities of trustees**

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the charitable company and considered the risk of such regulations, including fraud. We designed audit procedures to respond to the risk, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error.

We focused on laws and regulations relevant to the charitable company which could give rise to a material misstatement in the financial statements. Our testing included discussions with management with direct responsibility for the compliance of laws and regulations and agreeing financial statement disclosures to underlying supporting documentation. There are inherent limitations in the audit procedures described and, the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it.

As part of our audit, we addressed the risk of management override of internal controls, including testing of journals and review of the nominal ledger. We evaluated whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Auditor's report.

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**

**(A company limited by guarantee)**

---

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE (CONTINUED)**

---

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

**Philip Allsop (Senior statutory auditor)**

for and on behalf of

**BHP LLP**

Chartered Accountants

Statutory Auditor

2 Rutland Park

Sheffield

S10 2PD

Date:

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)**  
**FOR THE YEAR ENDED 31 MARCH 2021**

	Note	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
<b>Income from:</b>				
Donations and legacies		156,849	156,849	149,732
Other trading activities	2	77,526	77,526	140,940
Investments		77	77	(20)
		<u>234,452</u>	<u>234,452</u>	<u>290,652</u>
<b>Total income</b>				
<b>Expenditure on:</b>				
Cost of commercial trading operation		81,319	81,319	150,246
Charitable activities		119,830	119,830	212,692
		<u>201,149</u>	<u>201,149</u>	<u>362,938</u>
<b>Total expenditure</b>				
		<u>33,303</u>	<u>33,303</u>	<u>(72,286)</u>
<b>Net movement in funds</b>				
<b>Reconciliation of funds:</b>				
Total funds brought forward		148,643	148,643	220,929
Net movement in funds		33,303	33,303	(72,286)
		<u>181,946</u>	<u>181,946</u>	<u>148,643</u>
<b>Total funds carried forward</b>				

The Consolidated statement of financial activities includes all gains and losses recognised in the year.

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE****(A company limited by guarantee)**REGISTERED NUMBER: 03012351

---

**CONSOLIDATED BALANCE SHEET***AS AT 31 MARCH 2021*

---

	<b>Note</b>	<b>2021</b>	<b>2020</b>
		<b>£</b>	<b>£</b>
<b>Fixed assets</b>			
Tangible assets	7	<b>5,329</b>	7,125
		<hr/>	<hr/>
		<b>5,329</b>	7,125
<b>Current assets</b>			
Debtors	8	<b>57,854</b>	86,681
Cash at bank and in hand		<b>273,750</b>	203,417
		<hr/>	<hr/>
		<b>331,604</b>	290,098
Creditors: amounts falling due within one year	9	<b>(154,987)</b>	(148,580)
		<hr/>	<hr/>
<b>Net current assets</b>		<b>176,617</b>	141,518
		<hr/>	<hr/>
<b>Total assets less current liabilities</b>		<b>181,946</b>	148,643
		<hr/>	<hr/>
<b>Total net assets</b>		<b>181,946</b>	148,643
		<hr/> <hr/>	<hr/> <hr/>
<b>Charity funds</b>			
Restricted funds	10	-	-
Unrestricted funds	10	<b>181,946</b>	148,643
		<hr/>	<hr/>
<b>Total funds</b>		<b>181,946</b>	148,643
		<hr/> <hr/>	<hr/> <hr/>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

**Mr L Whitby**

Date:

The notes on pages 21 to 32 form part of these financial statements.

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE****(A company limited by guarantee)**REGISTERED NUMBER: 03012351

---

## COMPANY BALANCE SHEET

AS AT 31 MARCH 2021

---

	Note	2021 £	2020 £
<b>Fixed assets</b>			
Tangible assets	7	5,210	6,476
		<u>5,210</u>	<u>6,476</u>
<b>Current assets</b>			
Debtors	8	44,240	49,462
Cash at bank and in hand		186,651	171,999
		<u>230,891</u>	<u>221,461</u>
Creditors: amounts falling due within one year	9	(60,595)	(80,719)
		<u>170,296</u>	<u>140,742</u>
<b>Total assets less current liabilities</b>		<u>175,506</u>	<u>147,218</u>
<b>Total net assets</b>		<u>175,506</u>	<u>147,218</u>
<b>Charity funds</b>			
Restricted funds	10	-	-
Unrestricted funds	10	175,506	147,218
		<u>175,506</u>	<u>147,218</u>
<b>Total funds</b>		<u>175,506</u>	<u>147,218</u>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

**Mr L Whitby**

Date:

The notes on pages 21 to 32 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

**1. Accounting policies**

**1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

United Kingdom National External Quality Assessment Service meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated statement of financial activities (SOFA) and Consolidated balance sheet consolidate the financial statements of the Group and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The Group has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of financial activities in these financial statements.

**1.2 Company status**

The company is a company limited by guarantee. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

**1.3 Going concern**

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

**1.4 Income**

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

The following specific policies are applied to particular categories of income:

- Voluntary income is received by way of subscriptions and included in full in the Statement of Financial Activities when receivable.
- Investment income is included when receivable and represents interest earned on the charity's cash deposits.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**1. Accounting policies (continued)**

**1.5 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

**1.6 Basis for consolidation**

The financial statements consolidate the accounts of United Kingdom National External Quality Assessment Service and its wholly owned subsidiary company, Pathology Quality Assessment Limited.

The company has taken advantage of the exemption contained within section 408 of the Companies Act 2006 not to present its own Income and expenditure account.

The net income for the year dealt with in the accounts of the parent was £28,288 (2020: £60,020 net expenditure).

**1.7 Tangible fixed assets and depreciation**

All assets costing more than £200 are capitalised.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

Office equipment	- 25% per annum
------------------	-----------------

**1.8 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the bank.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

**1. Accounting policies (continued)**

**1.9 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Consolidated statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

**1.10 Operating leases**

Rentals paid under operating leases are charged to the Consolidated statement of financial activities on a straight line basis over the lease term.

**1.11 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**1.12 Cash at bank and in hand**

Cash at bank and in hand includes cash.

**1.13 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation.

**1.14 Financial instruments**

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**1.15 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

**1. Accounting policies (continued)**

**1.16 Amounts held on behalf of WHO Collaborating Centre**

On 22 March 2000, monies held by the Wolfson EQA laboratory Fund were transferred to the charity at request of the Charity Commission. The purpose of these funds were to enable the Wolfson EQA laboratory to function as a World Health Organisation Collaborating Centre for Research and Reference Services in Clinical Chemistry, and to advance education and promote the presentation of good health through quality assurance and assessment services in laboratory medicine worldwide. United Kingdom National External Quality Assessment Services is acting as custodian of these funds. Its trustees have no control over where the monies are spent and the charity charges a management fee for holding these funds. The monies are shown separately within creditors as amounts held on behalf of WHO Collaborating Centre, are held in a separate bank account and transactions relating to these funds are not included within the income and expenditure of the charity.

**2. Income from other trading activities**

**Income from non charitable trading activities**

	<b>Unrestricted funds 2021 £</b>	<b>Total funds 2021 £</b>	Total funds 2020 £
Precept subscriptions	59,517	<b>59,517</b>	70,895
Other income	4,814	<b>4,814</b>	1,454
Fund management fees	1,050	<b>1,050</b>	2,550
Participant's meeting sales	12,145	<b>12,145</b>	66,041
	<hr/> <b>77,526</b> <hr/>	<hr/> <b>77,526</b> <hr/>	<hr/> 140,940 <hr/>

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

**3. Total expenditure**

	Trading operation 2021 £	Charitable activities 2021 £	Total funds 2021 £	Total funds 2020 £
Participant meeting costs	17,556	-	<b>17,556</b>	62,962
Advisory panels	-	-	-	14,617
Cost of the executive	-	441	<b>441</b>	4,684
President's reimbursements	-	20,000	<b>20,000</b>	20,323
Cost of working groups	-	1,020	<b>1,020</b>	2,488
Cost of Steering Committees	-	41	<b>41</b>	19,550
Annual Meeting	-	-	-	39,669
Advertising and promotion	8,457	-	<b>8,457</b>	30,342
Wages and salaries	32,784	60,713	<b>93,497</b>	75,674
Temporary wage costs	2,382	6,672	<b>9,054</b>	34,070
Staff training	8,100	-	<b>8,100</b>	476
General office expenses	118	6,016	<b>6,134</b>	12,173
Operating lease rentals - land and buildings	2,639	3,959	<b>6,598</b>	6,414
Computer costs	1,687	4,881	<b>6,568</b>	7,542
Subscriptions	-	722	<b>722</b>	615
Bank charges	176	-	<b>176</b>	2,015
Sundry expenses	314	189	<b>503</b>	3,589
Auditor's remuneration	5,465	7,020	<b>12,485</b>	10,262
Auditor's remuneration - non audit fees	1,110	-	<b>1,110</b>	2,278
Depreciation	531	3,845	<b>4,376</b>	3,730
Professional fees	-	4,311	<b>4,311</b>	9,332
Hotels, travel and subsistence	-	-	-	133
<b>Total 2021</b>	<b>81,319</b>	<b>119,830</b>	<b>201,149</b>	<b>362,938</b>
Total 2020	150,246	212,692	362,938	

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

**4. Net income/(expenditure)**

This is stated after charging:

	<b>2021</b>	2020
	£	£
Depreciation of tangible fixed assets: - owned by the charitable group	<b>4,375</b>	3,730
Fees payable to the company's auditor in respect of:		
Auditor's remuneration - audit	<b>12,485</b>	10,262
Operating lease rentals - land and buildings	<b>6,598</b>	6,414
	<u><u>          </u></u>	<u><u>          </u></u>

**5. Auditors' remuneration**

The auditor's remuneration amounts to an audit fee of £12,485 (2020: £10,262) and non-audit services of £2,730 (2020: £1,110).

**6. Staff costs**

	<b>Group</b>	Group	<b>Company</b>	Company
	<b>2021</b>	2020	<b>2021</b>	2020
	£	£	£	£
Wages and salaries	<b>87,825</b>	70,232	<b>57,144</b>	42,376
Social security costs	<b>4,020</b>	4,009	<b>2,412</b>	2,405
Pension costs	<b>1,652</b>	1,433	<b>1,157</b>	1,027
	<u><u>93,497</u></u>	<u><u>75,674</u></u>	<u><u>60,713</u></u>	<u><u>45,808</u></u>

The average number of persons employed by the group during the year was as follows:

	<b>Group</b>	Group
	<b>2021</b>	2020
	<b>No.</b>	<b>No.</b>
	<b>2</b>	2
	<u><u>          </u></u>	<u><u>          </u></u>

No employee received remuneration amounting to more than £60,000 in either year.

---

UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE  
(A company limited by guarantee)

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

7. Tangible fixed assets

*Group*

	Office Equipment £
<b><i>Cost or valuation</i></b>	
At 1 April 2020	31,193
Additions	2,579
	<hr/>
At 31 March 2021	33,772
	<hr/>
<b><i>Depreciation</i></b>	
At 1 April 2020	24,068
Charge for the year	4,375
	<hr/>
At 31 March 2021	28,443
	<hr/>
<b><i>Net book value</i></b>	
At 31 March 2021	5,329
	<hr/> <hr/>
At 31 March 2020	7,125
	<hr/> <hr/>

UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE  
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

7. Tangible fixed assets (continued)

*Company*

	Fixtures and fittings £
<b>Cost or valuation</b>	
At 1 April 2020	29,076
Additions	2,579
At 31 March 2021	<u>31,655</u>
<b>Depreciation</b>	
At 1 April 2020	22,600
Charge for the year	3,845
At 31 March 2021	<u>26,445</u>
<b>Net book value</b>	
At 31 March 2021	<u>5,210</u>
At 31 March 2020	<u>6,476</u>

8. Debtors

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Trade debtors	56,173	79,370	32,353	31,174
Amounts owed by group undertakings	-	-	11,286	16,684
Other debtors	-	109	-	109
Prepayments and accrued income	1,681	7,202	601	1,495
	<u>57,854</u>	<u>86,681</u>	<u>44,240</u>	<u>49,462</u>

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

**9. Creditors: Amounts falling due within one year**

	<b>Group 2021 £</b>	<b>Group 2020 £</b>	<b>Company 2021 £</b>	<b>Company 2020 £</b>
Payments received on account	<b>56,067</b>	59,366	-	-
Trade creditors	<b>51,550</b>	4,144	<b>28,818</b>	2,303
Amounts held on behalf of WHO Collaborating Centre	<b>21,673</b>	22,261	<b>21,673</b>	22,261
Other taxation and social security	<b>10,595</b>	2,150	-	-
Other creditors	<b>15,102</b>	60,659	<b>10,104</b>	56,155
	<b>154,987</b>	148,580	<b>60,595</b>	80,719

---

UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE  
(A company limited by guarantee)

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

10. Statement of funds

Statement of funds - current year

	Balance at 1 April 2020 £	Income £	Expenditure £	Balance at 31 March 2021 £
<i>Unrestricted funds</i>				
General funds	<b>148,643</b>	<b>234,452</b>	<b>(201,149)</b>	<b>181,946</b>

Statement of funds - prior year

	Balance at 1 April 2019 £	Income £	Expenditure £	Balance at 31 March 2020 £
<i>Unrestricted funds</i>				
General funds	<b>220,929</b>	<b>290,652</b>	<b>(362,938)</b>	<b>148,643</b>

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

**11. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

	<b>Unrestricted funds 2021 £</b>	<b>Total funds 2021 £</b>
Tangible fixed assets	5,329	<b>5,329</b>
Current assets	331,604	<b>331,604</b>
Creditors due within one year	(154,987)	<b>(154,987)</b>
<b>Total</b>	<b>181,946</b>	<b>181,946</b>

**Analysis of net assets between funds - prior year**

	<b>Unrestricted funds 2020 £</b>	<b>Total funds 2020 £</b>
Tangible fixed assets	7,125	7,125
Current assets	290,098	290,098
Creditors due within one year	(148,580)	(148,580)
<b>Total</b>	<b>148,643</b>	<b>148,643</b>

**12. Operating lease commitments**

At 31 March 2021 the Group and the company had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	<b>Group 2021 £</b>	<b>Group 2020 £</b>
Not later than 1 year	<b>6,599</b>	6,414
Later than 1 year and not later than 5 years	<b>17,047</b>	22,303
	<b>23,646</b>	28,717

---

**UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE**  
**(A company limited by guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
*FOR THE YEAR ENDED 31 MARCH 2021*

---

**13. Related party transactions**

There were 15 directors/ trustees (2020: 15) who served during the period. No directors' trustees received remuneration during the period.

During the year, there were no expenses reimbursed to trustees (2020: £5,444 reimbursed to 9 trustees for attendance at executive meetings and other activities).

During the year, the company paid £20,000 (2020: £20,000) to Sheffield Teaching Hospital NHS Foundation Trust for the services of L Whitby, trustee.

The majority of the trustees of the charity are also employees of the schemes which contribute £235,531 (2020: £235,531) to the charitable group's income. Disclosure of each individual transaction would result in unnecessary costs and delay due to the number of transactions between the charity and the schemes.

The charitable company owns 100% of its subsidiary Pathology Quality Assessment Limited. During the year, expenditure was recharged of £13,420 to the subsidiary company (2020: £14,066). At the year end amounts totalling £11,286 (2020: £16,684) are included in debtors owed to the parent charitable company.

**14. Principal subsidiaries**

The following was a subsidiary undertaking of the company:

<b>Name</b>	<b>Company number</b>	<b>Holding</b>
Pathology Quality Assessment Limited	05423205	100%

The financial results of the subsidiary for the year were:

<b>Name</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Profit/(Loss)/ Surplus/ (Deficit) for the year £</b>	<b>Net assets £</b>
Pathology Quality Assessment Limited	77,586	(72,570)	5,016	6,440